Clinical Trial Update: Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a combination of bendamustine, weekly bortezomib, lenalidomide and dexamethasone for multiple myeloma was terminated, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bendamustine (Treanda) (bendamustine)
• Bortezomib (Velcade) (Bortezomib)
• Dexamethasone (Decadron) (dexamethasone)
• Lenalidomide (Revlimid) (lenalidomide)

Snippet

Sponsor: Loyola University | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-07-10